KR102603756B1 - 글리코펩티드 조성물 - Google Patents

글리코펩티드 조성물 Download PDF

Info

Publication number
KR102603756B1
KR102603756B1 KR1020177015221A KR20177015221A KR102603756B1 KR 102603756 B1 KR102603756 B1 KR 102603756B1 KR 1020177015221 A KR1020177015221 A KR 1020177015221A KR 20177015221 A KR20177015221 A KR 20177015221A KR 102603756 B1 KR102603756 B1 KR 102603756B1
Authority
KR
South Korea
Prior art keywords
delete delete
vancomycin
acetyl
alanine
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177015221A
Other languages
English (en)
Korean (ko)
Other versions
KR20170078830A (ko
Inventor
이보나 자스프리카
사비나 케저
카타리나 핀드릭
Original Assignee
셀리아 파마슈티칼즈 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102603756(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀리아 파마슈티칼즈 에이피에스 filed Critical 셀리아 파마슈티칼즈 에이피에스
Priority to KR1020237020985A priority Critical patent/KR102763211B1/ko
Publication of KR20170078830A publication Critical patent/KR20170078830A/ko
Application granted granted Critical
Publication of KR102603756B1 publication Critical patent/KR102603756B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020177015221A 2014-11-06 2015-11-06 글리코펩티드 조성물 Active KR102603756B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020985A KR102763211B1 (ko) 2014-11-06 2015-11-06 글리코펩티드 조성물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US62/076,400 2014-11-06
US201562168749P 2015-05-30 2015-05-30
US62/168,749 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020985A Division KR102763211B1 (ko) 2014-11-06 2015-11-06 글리코펩티드 조성물

Publications (2)

Publication Number Publication Date
KR20170078830A KR20170078830A (ko) 2017-07-07
KR102603756B1 true KR102603756B1 (ko) 2023-11-16

Family

ID=54478023

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177015221A Active KR102603756B1 (ko) 2014-11-06 2015-11-06 글리코펩티드 조성물
KR1020237020985A Active KR102763211B1 (ko) 2014-11-06 2015-11-06 글리코펩티드 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237020985A Active KR102763211B1 (ko) 2014-11-06 2015-11-06 글리코펩티드 조성물

Country Status (29)

Country Link
US (8) US10188697B2 (enExample)
EP (4) EP3834837A1 (enExample)
JP (2) JP6797795B2 (enExample)
KR (2) KR102603756B1 (enExample)
CN (1) CN107073072B (enExample)
AU (1) AU2015341763B2 (enExample)
BR (1) BR112017009405B1 (enExample)
CL (1) CL2017001139A1 (enExample)
CO (1) CO2017005391A2 (enExample)
CR (1) CR20170234A (enExample)
CY (2) CY1122960T1 (enExample)
DK (2) DK3215173T3 (enExample)
EA (1) EA035368B1 (enExample)
ES (2) ES2852550T3 (enExample)
HR (2) HRP20200101T1 (enExample)
HU (2) HUE049857T2 (enExample)
IL (1) IL252120B (enExample)
MX (1) MX387229B (enExample)
NZ (1) NZ731955A (enExample)
PH (1) PH12017500720A1 (enExample)
PL (2) PL3215173T3 (enExample)
PT (2) PT3542812T (enExample)
RS (2) RS59851B1 (enExample)
SA (1) SA517381446B1 (enExample)
SG (1) SG11201703568WA (enExample)
SI (2) SI3542812T1 (enExample)
TN (1) TN2017000182A1 (enExample)
WO (1) WO2016071495A1 (enExample)
ZA (1) ZA201702767B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
WO2017111601A1 (en) * 2015-12-24 2017-06-29 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
MX388732B (es) * 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
WO2018096556A1 (en) * 2016-11-23 2018-05-31 Gufic Biosciences Limited Lyophilized pharmaceutical compositions of dalbavancin
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
US20220184173A1 (en) 2019-03-08 2022-06-16 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11433115B2 (en) * 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832B (zh) * 2021-09-14 2026-06-16 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (enExample) * 2022-03-08 2023-09-14
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
CN117618337A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的糖肽类抗生素水溶液及其制备方法和用途
UY40482A (es) * 2022-10-12 2024-04-30 Hikma Pharmaceuticals Usa Inc Composición líquida de dalbavancina.
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085526A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
NZ270387A (en) 1994-01-28 1996-11-26 Lilly Co Eli Glycopeptide antibiotic, its production and compositions thereof
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
US7022712B2 (en) * 2002-03-26 2006-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
CN1826129A (zh) * 2002-07-09 2006-08-30 尖端医疗有限公司 与异亮氨酸硼脯氨酸化合物相关的方法和组合物
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
EP1565201B1 (en) 2002-11-18 2018-10-31 Vicuron Pharmaceuticals, Inc. Methods of administering dalbavancin for treatment of bacterial infections
EP1848413B1 (en) 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
SG195038A1 (en) * 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
US20150182667A1 (en) 2012-08-08 2015-07-02 Vanderbilt University Composition with Biofilm Dispersal Agents
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
ES3057232T3 (en) 2014-03-14 2026-02-27 Azurity Pharmaceuticals Inc Composition and method for vancomycin oral liquid
WO2016071495A1 (en) * 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085526A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. Bardsley 등, J. Chem. Soc., Perkin Trans. 2, p.598-603 (2002)*
C.M. Harris 등, J. Antibiotics, 38(1), p.51-57 (1985.01.31.)*

Also Published As

Publication number Publication date
HRP20200101T1 (hr) 2020-04-03
EP3542812A1 (en) 2019-09-25
EP3215173B8 (en) 2020-03-11
US20210220433A1 (en) 2021-07-22
US20170348385A1 (en) 2017-12-07
RS61418B1 (sr) 2021-03-31
HUE049857T2 (hu) 2020-10-28
SI3542812T1 (sl) 2021-04-30
SI3215173T1 (sl) 2020-03-31
US10849956B2 (en) 2020-12-01
DK3215173T3 (da) 2020-03-23
HRP20210342T8 (hr) 2022-01-21
EP3542812B1 (en) 2021-01-13
US20190160142A1 (en) 2019-05-30
BR112017009405B1 (pt) 2024-02-06
JP6797795B2 (ja) 2020-12-09
US12161690B2 (en) 2024-12-10
ES2769849T3 (es) 2020-06-29
US20230158101A1 (en) 2023-05-25
EA035368B1 (ru) 2020-06-03
US20200069768A1 (en) 2020-03-05
HUE053347T2 (hu) 2021-06-28
CY1122960T1 (el) 2021-10-29
KR102763211B1 (ko) 2025-02-04
US20220354927A1 (en) 2022-11-10
EP4147710B1 (en) 2026-07-01
EP3215173B1 (en) 2020-01-01
JP2020183424A (ja) 2020-11-12
CO2017005391A2 (es) 2017-10-31
EP3215173A1 (en) 2017-09-13
AU2015341763B2 (en) 2019-01-17
SA517381446B1 (ar) 2020-09-21
IL252120A0 (en) 2017-07-31
EA201790997A1 (ru) 2017-09-29
TN2017000182A1 (en) 2018-10-19
AU2015341763A1 (en) 2017-06-08
US20180133286A1 (en) 2018-05-17
PT3215173T (pt) 2020-04-03
US10039804B2 (en) 2018-08-07
MX387229B (es) 2025-03-04
CN107073072A (zh) 2017-08-18
CR20170234A (es) 2018-01-15
KR20170078830A (ko) 2017-07-07
JP2017533218A (ja) 2017-11-09
IL252120B (en) 2020-07-30
NZ731955A (en) 2023-07-28
PH12017500720A1 (en) 2017-10-09
KR20230096142A (ko) 2023-06-29
HRP20210342T1 (hr) 2021-04-30
US11000567B2 (en) 2021-05-11
PL3542812T3 (pl) 2021-07-12
PT3542812T (pt) 2021-04-20
JP7032488B2 (ja) 2022-03-08
US10188697B2 (en) 2019-01-29
WO2016071495A1 (en) 2016-05-12
ZA201702767B (en) 2018-12-19
SG11201703568WA (en) 2017-05-30
CL2017001139A1 (es) 2017-12-01
PL3215173T3 (pl) 2020-05-18
EP3834837A1 (en) 2021-06-16
ES2852550T3 (es) 2021-09-13
MX2017005749A (es) 2018-01-11
US20250288640A1 (en) 2025-09-18
US11517609B2 (en) 2022-12-06
BR112017009405A2 (pt) 2018-01-02
CA2964524A1 (en) 2016-05-12
CN107073072B (zh) 2021-06-18
RS59851B1 (sr) 2020-02-28
CY1124011T1 (el) 2022-05-27
EP4147710A1 (en) 2023-03-15
US11628200B2 (en) 2023-04-18
DK3542812T3 (da) 2021-04-12

Similar Documents

Publication Publication Date Title
US11517609B2 (en) Glycopeptide compositions
AU2017262943B2 (en) Stabilized glycopeptide antibiotic formulations
WO2024079224A1 (en) Liquid dalbavancin composition
CA2964524C (en) Glycopeptide compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)